How supplied: 1 mg and 2.5 mg tablets
Naratriptan is generally not prescribed under these conditions:
- presence or risk factors for coronary artery disease
- uncontrolled hypertension
- basilar or hemiplegic Migraines
- Do NOT take Amerge within 24 hours of taking any other triptan unless specifically told to do so by your doctor.
- Do NOT take Amerge within 24 hours of taking any ergotamine medication such as DHE or Migranal.
Pregnancy and Breastfeeding:
- FDA pregnancy category C. This means that it is not known whether this drug will harm an unborn baby. Do not take this medication without first talking to your doctor if you are pregnant or could become pregnant during treatment.
- It is not known whether this medication passes into breast milk. Do not take without talking to your doctor if you are breast-feeding a baby.
Other medical conditions:
The presence of other medical problems may affect the use of naratriptan. Make sure you tell your doctor if you have any other medical problems, especially those listed below. Heart or blood vessel disease and high blood pressure sometimes do not cause any symptoms, so some people do not know that they have these problems. Before deciding whether you should use naratriptan, your doctor may need to do some tests to make sure that you do not have any of these conditions.
- angina, heart or blood vessel disease
- uncontrolled high blood pressure
- kidney disease
- liver disease
- stroke (history of)--The chance of side effects may be increased.
- basilar or hemiplegic Migraine
Be sure to tell your doctor if you are taking any other prescription or over-the-counter medications, especially other prescription medicine for Migraine or depression.
- Do not take sumatriptan if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) within the last 14 days. The combination could cause seizures, nausea, vomiting, sweating, flushing, and dizziness.
- Do not take sumatriptan if you have taken any of the following medicines within the previous 24 hours:
- ergot-based medications such as methysergide (Sansert), ergotamine (Ergostat), dihydroergotamine (D.H.E., Migranal Nasal Spray), and ergotamine combination products (Cafergot, Ercaf, Wigraine, Cafatine, Cafatine-PB, Cafetrate).
- another triptan such as rizatriptan (Maxalt, Maxalt-MLT), naratriptan (Amerge), zolmitriptan (Zomig), almotriptan (Axert), frovatriptan (Frova), or eletriptan (Relpax).
Potential side effects:
- Stop using this medicine and check with your doctor immediately if any of the following side effects occur:
- an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives)
- an irregular heartbeat or tightness, pain, pressure or heaviness in your chest, throat, neck, or jaw.
- Some of the following effects, such as
nausea, vomiting, drowsiness, dizziness, and general feeling of illness
or tiredness, often occur during or after a migraine, even when
naratriptan has not been used. However, check with your doctor if any of
the following side effects continue or are bothersome:
- dry mouth
- drowsiness or dizziness
- tingling, flushing, warmth, redness, tightness, or heaviness in a body part
- muscle tiredness or weakness
- U.S.: Amerge
- Canada: Naramig
- U.K.: Naramig
- Australia: Naramig
Amerge To Prevent Menstrual
In a recent double-blind study, Amerge was found effective for preventing menstrually associated migraines and reducing the duration of break though migraines.
Triptans: Overview and Profiles
In 1992, the FDA approved the first of a class of medications that many Migraineurs call "miracle drugs." That drug was sumatriptan (Imitrex®, Imigran®), the first triptan. Here are both general information on triptans and detailed profiles of each.
Triptans Pose Less Risk Than OTC Meds for Some Patients
Since triptans (Imitrex/sumatriptan, Maxalt/rizatriptan, etc.) were introduced in 1992, some doctors have been reluctant to prescribe them because of concerns about cardiovascular safety. Some refused to prescribe them for patients beyond a certain age even if they had no history of or risk factors for coronary artery disease. A new report offers evidence of their safety for those patients.
- FDA information sheet
- FDA-approved prescribing info (Requires free Adobe Acrobat Reader)